In 1938, 2 astute female scientists, Grace Eldering and Pearl Kendrick, discovered a new bacterial species among isolates collected from patients with whooping cough. Although the new strain resembled both Bordetella pertussis and B. bronchiseptica, it was biochemically identical with neither. They deemed it a new species and named it Bacillus parapertussis [1] . At the same time, this new species was also identified by Bardford and Slavin [2] .
Pertussis-like illness may be caused by Bordetella species other than pertussis, including parapertussis, holmesii and bronchiseptica [2] . B. parapertussis might vary from an unrecognized infection to a mild illness or typical pertussis presentation; it is increasingly recognized and reported to public health agencies [2, 3] . B. parapertussis illness remains underestimated, however, because many laboratories do not differentiate among Bordetella species, and only B. pertussis is reportable in most states [4, 5] . In Oregon, B. parapertussis infections are not specifically reportable, but many laboratories nevertheless include them in public health reporting.
During 2011-2016, the Oregon Public Health Division was notified of 104 cases of B. parapertussis infection among children age 2 months to 10 years. We assessed the effectiveness of prior pertussis vaccination against reported B. parapertussis infections, using data from Oregon's statewide reportable disease surveillance system "Orpheus" and population-based immunization information system "ALERT IIS."
METHODS

Case Data
We reviewed Orpheus for laboratory-confirmed B. pertussis and B. parapertussis infections reported among Oregon children 2 months-10 years of age during 2011-2016. Pertussis cases were defined by having a specimen positive for only B. pertussis, using polymerase chain reaction (PCR) test or culture. Parapertussis cases were defined by PCR or culture indicating only B. parapertussis.
Vaccination Data
Histories of vaccination with diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine (DTaP) were ascertained for each case from ALERT IIS. In Oregon during the study period, >95% of children had pertussis immunization records submitted to ALERT IIS. Cases were considered fully vaccinated if they were up to date for age according to the Advisory Committee on Immunization Practices (ACIP)-recommended schedule: one DTaP by 2-3 months of age, 2 DTaP by 4-5 months of age, 3 DTaP by 6-14 months of age, four DTaP by 15 months -3 years of age, and 5 DTaP shots by 4-10 years of age (or 4 shots, if the 4th was given after the 4th birthday). Patients with pertussis were excluded from analysis if they had received pertussis-containing vaccine within 14 days of disease onset. The median time lag between specimen collection date and onset date for all pertussis cases was 10 days. Because they are not officially reportable in Oregon, reported Bordetella parapertussis infections were not investigated by public health officials, so illness onset dates were typically not captured; therefore, we inferred a similar lag time to that of pertussis cases-median of 10 (interquartile range, 5−17) days-and excluded parapertussis cases from analysis if pertussis vaccine had been received during the 24 (i.e., 14 + 10) days before the specimen collection date.
Population Denominators
Population figures from the Portland State University Population Research Center, along with Oregon ALERT IIS records for pertussis-containing immunizations, were used in estimating immunization rates by age during 2011-2016.
Vaccine Effectiveness Calculations
We calculated vaccine effectiveness (VE) by 2 methods: AR unvaccinated ]) × 100%, where AR was the attack rate [6] . b) Indirect cohort method: This method has been used to calculate a vaccine's relative effectiveness against specific strains of pathogens (e.g., pneumococci) incorporated into a vaccine, compared with nonvaccine strains. An assumption that the vaccine induces no protection whatsoever against illness caused by nonvaccine strains allows for a straightforward calculation of VE as [1 -(a*d)/(b*c)], where a = cases of vaccine-strain illness among vaccinated persons, b = cases of nonvaccine-strain illness among vaccinated persons, c = vaccine-strain cases among unvaccinated persons, and d = non-vaccine-strain cases among unvaccinated persons [7] . In our adaptation of this method, the "nonvaccine strain" was B. parapertussis.
A refinement of the indirect cohort method is possible when VE against disease caused by the vaccine strain is known a priori in the study population [8] . Based on the above methods, VE against the 2 diseases can be written as: ( )
Given that the vaccinated and unvaccinated populations are the same regardless of whether pertussis or parapertussis VE is being considered, the equations can be combined and reduced to the following:
Therefore, if VE pertussis is known, then VE parapertussis can be calculated from parapertussis case counts among vaccinated and unvaccinated persons. If the vaccine has no effectiveness against disease caused by the nonvaccine strain (i.e., if VE parapertussis = 0), then the above equation reduces to the wellknown VE pertussis = 1 -(ad/bc). Using previously published estimates of VE pertussis among Oregon children, we used the above equation as a population-independent check on our VE parapertussis calculation. The previously published VE pertussis was 89.7% (95% CI, 87.0%-91.8%) [8] .
RESULTS
In sum, 104 Oregon children 2 months to 10 years of age were reported with culture or PCR test indicating B. parapertussis infection during 2011-2016. Three cases were excluded for having been vaccinated within the 24 days before the specimen collection date. Among the parapertussis cases, 71 (70%) were up-to-date with pertussis vaccination, 15 (15%) were completely unvaccinated, and the remainder were partially vaccinated. During the same period, 1,521 laboratory-confirmed B. pertussis infections were reported among Oregon children 2 months to 10 years of age; 50 were excluded for having been vaccinated during the 14 days before disease onset. Among the pertussis cases, 706 (48%) were up-to-date with pertussis vaccination, and 485 (33%) were completely unvaccinated.
VE parapertussis calculated by the relative risk method ranged from 67% among children 2-14 months of age to 93% among children 7-10 years of age (Table 1) . For all cases 2 months to 10 years of age, VE parapertussis was 82% (95% CI, 69%-90%).
As a check on the relative risk method above, the VE parapertussis calculated by our modified indirect method for all cases 2 months to 10 years of age was 66% (95% CI, 59%-75%). These 2 results are both statistically significant but are not significantly different from each other.
DISCUSSION
To our knowledge, this is the second study to show significant protection of acellular pertussis vaccines against illness caused by B. parapertussis and the first to employ immunization registry and statewide reportable disease data to estimate real-world VE against parapertussis on a population basis [9] . We found pertussis vaccination effective against parapertussis by both the VE methodology recommended by Orenstein [6] and by our modification of the "indirect cohort" method [7] . Pertussis remains a poorly controlled vaccine-preventable disease that will vex the population and public health officials for the foreseeable future. Nevertheless, recent studies have shown that pertussis vaccines provide clinically important protection: vaccinated persons are significantly less likely than unvaccinated ones to suffer pertussis [8] . Our data show that prevention of parapertussis and its attendant costs is a modest side benefit of vaccination against pertussis using acellular vaccine. As in the case of pertussis, however, any immunity against parapertussis afforded by vaccination (or by infection) might be expected to wane.
The incidence of infections caused by B. parapertussis is not well known. Because distinguishing among Bordetella species is not universal among testing laboratories, and because parapertussis is not reportable in most jurisdictions, many parapertussis cases might be misreported as "pertussis" or remain unreported. A study conducted among 9 states during 2008-2010 found that of upper respiratory specimens with PCR-identified insertion sequences indicating either B. pertussis or B. parapertussis, 14% were identified as B. parapertussis [10] . B. parapertussis accounted for 2.1% to 25% of culture-positive specimens during European vaccine efficacy trials [10] .
Secondary analyses of data from acellular pertussis vaccine efficacy trials have arrived at varying estimates of efficacy against parapertussis. Trials in Italy and Sweden did not find substantial efficacy [11, 12] . However, post hoc analysis of a German trial found the acellular vaccine 50% (95% CI, 5%-74%) efficacious against parapertussis, while the efficacy of the whole-cell vaccine used in this study against parapertussis was a statistically nonsignificant 21% [9] . The large amount of filamentous hemagglutinin (FHA) in the acellular vaccine, and the commensurately greater anti-FHA antibody response induced by it, might explain better protection afforded by acellular vaccine against parapertussis [9] .
Our study has several limitations. First, some parapertussis cases might be misclassified as pertussis if discriminatory testing were not performed, thereby biasing the calculated VE toward the null. There are no known selection biases in terms of vaccination history; when ordering the tests, physicians could not know whether results would return pertussis or parapertussis. The gold-standard test-culture-for Bordetella spp. has become rare, and PCR leaves room for false-positive results for all cases. We consider our observational study exploratory and encourage similar analyses from other jurisdictions.
Notes
